March 17, 2025 – AstraZeneca, a prominent biopharmaceutical company, announced plans to acquire Belgian biotechnology firm EsoBiotec for around US$ 1 billion on Monday. The company will pay an initial payment of US$ 425 million and may spend around US$ 575 million more in achieving development and regulatory milestones.
The new acquisition is aimed at enhancing AstraZeneca’s cell therapy capabilities. The company will utilize EsoBiotec’s innovative Engineered NanoBody Lentiviral (ENaBL) platform to quickly develop next-generation cell therapies for treating cancer and autoimmune diseases.
EscoBiotec’s ENaBL platform has the tendency to genetically modify immune cells directly inside the body. By doing so, it allows for the creation of transformative cell therapy treatments in just minutes, compared to weeks with conventional methods.
According to AstraZeneca’s officials, the transaction will likely close in the second quarter of 2025. The acquisition is expected to help AstraZeneca to combat the global burden of a variety of chronic diseases as well as strengthen its position in the global cell therapy industry.
“Novel technologies like EscoBiotec’s ENaBL platform are expected to pave way for the development of advanced cell therapy treatments. Conventional cell therapies take weeks as they need cells to be removed from a patient, genetically modified outside the body, and finally readministered to the patient as a medicine. To address this, AstraZeneca will use EsoBiotec’s ENaBL platform to modify immune cells directly with the patient’s body, thereby reducing complexities and manufacturing timelines, says a senior analyst at CMI.”
EscoBiotec’s acquisition aligns with AstraZeneca’s ongoing efforts to boost its cell therapy capabilities. It will complement the company’s previous investments in CAR-T and T-cell receptor therapies for solid tumors.
- The ENaBL platform will help reduce the complexity and costs associated with cell therapy manufacturing. This could make advanced therapies more accessible to a broader patient pool, leading to significant growth in the global cell therapy industry.
Sources:
News Outlet: Reuters
Company: EsoBiotec
